Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus

• Published in: Curēus (Palo Alto, CA) CA), 2023-10, Vol.15 (10), p.e47190-e47190
• Main Authors: Panneerselvam, P, Biswas, Dibakar, Singh, Hema, Dilip Kumar, K, Ravi Kumar, P, Kalra, Pramila, Revankar, Santosh, Warrier, Sona
• Format: Article
• Language: English
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.47190

BACKGROUND AND OBJECTIVE The therapeutic use of vildagliptin and insulin (VIL-INS) or vildagliptin and metformin in combination with insulin (VIL-MET-INS) in the Indian scenario has yet to be explored by generating real-world evidence. Therefore, the present study aimed to evaluate the demographic, clinical characteristics, and treatment patterns of patients with type 2 diabetes mellitus (T2DM) in Indian settings in the above context.METHODOLOGY This observational study conducted at 600 healthcare centers in India retrospectively analyzed data of adult patients with T2DM who had been treated with either vildagliptin with insulin or a combination of vildagliptin and metformin with insulin. Data were collected from medical records and analyzed by appropriate statistical tests.RESULTS A total of 12,603 patients with T2DM were included with a mean age of 53.4 years of which 63.8% were males. The majority of patients (n=6511; 51.7%) received a combination of vildagliptin and metformin on top of insulin. A significantly high proportion of patients in the age group of 18-40 years received this treatment compared to patients who were initiated on insulin treatment after vildagliptin and metformin combination (11.6% vs. 9.7%; P